Quantcast
Home > Quotes > RGLS
RGLS

Regulus Therapeutics Inc. Common Stock (RGLS) Quote & Summary Data

$0.2869
*  
0.0126
4.21%
Get RGLS Alerts
*Delayed - data as of Jul. 16, 2018  -  Find a broker to begin trading RGLS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 0.3159 / $ 0.2707
Share Volume
681,789
50 Day Avg. Daily Volume
517,655
Previous Close
$ 0.2995
52 Week High / Low
$ 1.52 / $ 0.2881
Market Cap
29,929,279
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
681,789
50 Day Avg. Daily Volume:
517,655

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.88

Trading Range

The current last sale of $0.2869 is -0.42% Lower than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.3159 $ 1.52
 Low: $ 0.2707 $ 0.2881

Company Description (as filed with the SEC)

Item 1. Business Overview We are a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. We were formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. Our two lead product candidates, RG-012 and RGLS4326, are currently in clinical development. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease with no approved therapy available.  ... More ...  

Risk Grade

Where does RGLS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.3024
Open Date:
Jul. 16, 2018
Close Price:
$ 0.2869
Close Date:
Jul. 16, 2018

Consensus Recommendation

Analyst Info